Abstract
Purpose: Gastric cancer (GC) ranks as the fifth most prevalent malignancy globally, with substantial geographical disparities in incidence rates. The identification of novel pathogenic drivers and their pharmacological inhibitors is therefore critical for advancing precision therapeutics in GC. Based on our prior studies, this paper elucidates the role of Calreticulin (CALR) in regulating gastric cancer cell proliferation and identifies candidate targeted therapeutics.
Methods: We characterized the regulatory role of CALR in gastric cancer cell proliferation and developed yxx1121, a first-in-class small-molecule inhibitor targeting CALR protein stability. Furthermore, we elucidated the mechanistic basis of CALR-mediated oncogenic regulation in gastric carcinogenesis.
Results: CALR regulates GC cell proliferation both in vitro and in vivo. Knockdown of CALR significantly promoted GC cell apoptosis, while CALR overexpression markedly suppressed it. CALR inhibition induced G1 phase arrest in GC cells, blocked S phase progression, promoted apoptosis, and inhibited proliferation. Mechanistically, CALR likely modulates GC cell proliferation by regulating the expression and phosphorylation levels of CASP9, c-Myc, p-EGFR, p-STAT3, p-PI3K, and p-AKT. The identified small-molecule inhibitor yxx1121 potently suppressed GC cell proliferation.
Conclusion: We demonstrate CALR's essential mitotic control in GC models, mechanistically linking its regulation of both apoptotic (CASP9/c-Myc) and oncogenic (EGFR/STAT3/PI3K/AKT) pathways. The first-in-class CALR destabilizer yxx1121 effectively inhibits GC proliferation, positioning it as a promising therapeutic for CALR-dependent gastric cancers.
Introduction
Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, particularly in East Asia. Despite advancements in surgical techniques and chemotherapy, the molecular heterogeneity of the disease often leads to drug resistance and poor long-term survival. Identifying specific molecular drivers that can be targeted with precision medicine is essential for improving patient outcomes.
Calreticulin (CALR) is a multifunctional protein typically localized in the endoplasmic reticulum, known for its roles in protein folding and calcium homeostasis. Recent evidence has suggested its involvement in various malignancies, yet its specific contribution to gastric cancer progression was not fully understood. This study investigates CALR as a critical driver of GC proliferation and introduces a novel pharmacological approach to inhibit its activity.
Methods
The study employed a multi-disciplinary approach to validate CALR as a target and evaluate the efficacy of a new inhibitor:
- Cell Engineering: Human gastric cancer cell lines (AGS, MGC-803, and SGC-7901) were utilized. The team established stable lines that either overexpressed CALR or utilized RNA interference (knockdown) to silence the gene.
- Small-Molecule Screening: An in-house library of synthetic compounds was screened to identify molecules capable of suppressing GC cell growth in a CALR-dependent manner.
- Biophysical Characterization: Surface Plasmon Resonance (SPR) was used to determine the binding affinity between the lead compound, yxx1121, and the CALR protein.
- In Silico Modeling: Molecular docking and Molecular Dynamics (MD) simulations were performed to visualize the physical interaction between yxx1121 and the CALR protein structure.
- In Vivo Validation: Nude mice xenograft models were used to confirm the correlation between CALR expression and tumor volume/weight in a living system.
Results
CALR as a Mitotic Regulator
The research established that CALR exerts essential control over the cell cycle in gastric cancer. Inhibiting CALR expression caused cells to arrest in the G1 phase, preventing DNA replication (S phase) and triggering apoptosis. Conversely, overexpression of CALR significantly enhanced cell survival and proliferation.
Mechanism of Action for yxx1121
The lead compound, yxx1121, was identified as a potent CALR inhibitor. SPR analysis showed a strong binding affinity with a dissociation constant ($K_D$) of $4.96 \times 10^{-6}$ M. A key finding was that yxx1121 acts as a protein destabilizer. While treatment with the compound actually led to an increase in CALR mRNA levels—likely a compensatory cellular response—the actual protein levels dropped significantly. This suggests that yxx1121 promotes the degradation of CALR after translation rather than inhibiting gene transcription.
Pathway Modulation
Mechanistically, CALR regulates GC proliferation through a dual-pathway system. It simultaneously suppresses apoptotic signals (the CASP9/c-Myc axis) and amplifies oncogenic growth signals (the EGFR/STAT3/PI3K/AKT pathway). Western blot analysis confirmed that CALR inhibition led to a marked reduction in the phosphorylation (activation) of key drivers such as p-AKT, p-PI3K, and p-EGFR.
Therapeutic Efficacy
In cellular assays, yxx1121 treatment reduced proliferation by 73.5% in CALR-overexpressing cells, compared to a 52.7% reduction in control cells. This indicates that the compound is particularly effective against tumors with high CALR expression, supporting its potential as a precision therapeutic.
Discussion and Conclusion
This study identifies CALR as a critical "mitotic master switch" in gastric cancer and provides a proof-of-concept for its pharmacological inhibition. The development of yxx1121 as a first-in-class protein destabilizer offers a novel strategy for treating GC, particularly for patients whose tumors exhibit CALR upregulation.
While the results are promising, further research is required to fully elucidate the specific degradation machinery (such as the ubiquitin-proteasome system) utilized by yxx1121. Additionally, future in vivo studies will focus on the pharmacokinetic profile and safety of the compound in complex biological systems. Ultimately, CALR represents a viable therapeutic target, and yxx1121 serves as a promising lead for the next generation of gastric cancer treatments.
Summary updated